Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070782 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
A Phase 2 study, sponsored by Akcea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT03070782: Completed Phase 2 study, sponsored by Akcea Therapeutics.
NCT03070782 is a Phase 2 study that has completed, run by Akcea Therapeutics. The registered enrollment target is 286 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03070782, a Phase 2 study, has completed, sponsored by Akcea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) \[Lp(a)\] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Primary Outcome
An ANCOVA model was performed on the log ratio of Lp(a) value at the Primary Analysis Time Point to Lp(a) value at Baseline. The estimate of the log ratio was converted back to the original scale and percent change was calculated using formula: = (ratio of Lp(a) value at the Primary Analysis Time Point to Lp(a) value at Baseline - 1) × 100.
Interventions
- DRUG Placebo
- DRUG ISIS 681257
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2018-11-13 |
| Phase | Phase 2 |
What the finished NCT03070782 record still lists
NCT03070782 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03070782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03070782 about?
NCT03070782 is a clinical study titled "Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease". This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) \[Lp(a)\] levels in participa...
What is the current status of trial NCT03070782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2017-03-07. Estimated completion is 2018-11-13.
What interventions are being tested in trial NCT03070782?
The interventions under investigation include: Placebo (DRUG), ISIS 681257 (DRUG).
Who is sponsoring clinical trial NCT03070782?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03070782's enrollment target sits among peer trials
286 191st of 2000 higher than 1,809 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI